Cognitive & neuro
Glatiramer acetate
A synthetic polypeptide that dampens autoimmune attack in relapsing multiple sclerosis.
What it is
Glatiramer acetate (Copaxone) is not a single peptide but a defined mixture of synthetic polypeptides built from four amino acids - glutamate, lysine, alanine and tyrosine - in a fixed ratio. It was designed to mimic myelin basic protein and turned out to shift the immune response away from attacking myelin. It is licensed for relapsing-remitting multiple sclerosis.
How it works
- 1
Binds MHC class II molecules and competes with myelin antigens for presentation.
- 2
Shifts T helper cells toward anti-inflammatory, regulatory phenotypes.
- 3
Induces myelin-reactive T cells that secrete anti-inflammatory cytokines.
- 4
Promotes repair-supporting behaviour in antigen-presenting cells.
- 5
Its heterogeneous polypeptide mixture is why it is regulated as a complex biological mixture.
What it's studied for
Reported and studied effects
- Roughly 29% reduction in annualised relapse rate versus placebo in the pivotal trial
- Fewer new MRI lesions
- Modest effect on disability progression over years
- Frequent injection-site reactions and a post-injection flushing reaction
Research protocol notes
Research context onlyResearch context only - prescription medicine. Licensed regimens are 20 mg subcutaneously once daily or 40 mg three times weekly; the pivotal trial ran two years with annualised relapse rate as the primary endpoint, and extension cohorts have followed patients for over a decade, though not in a controlled design.
These figures are described so you can understand what researchers did. They are not a dose, a schedule, or a suggestion — and they are not a substitute for a doctor.
Possible side effects and contraindications
Safety profile
Possible side effects
- Injection-site reactions, including lipoatrophy with long-term use
- Post-injection reaction with flushing, chest tightness and palpitations
- Headache
- Nausea
- Arthralgia
- Rarely, a systemic hypersensitivity reaction
Contraindications and cautions
- Prior hypersensitivity
- Pregnancy - use only if clearly needed
- Not for primary progressive multiple sclerosis, where it has no evidence
A side-effect list is never complete, and these are not the only situations that warrant caution. Anything unexpected, or anything you are unsure about, should be discussed with a doctor before use.
Evidence assessment
A pivotal randomised placebo-controlled trial with relapse rate and MRI endpoints, plus two decades of follow-up data, and regulatory approval worldwide.
References
- 01Johnson et al., Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis, Neurology 1995
- 02European Medicines Agency - Copaxone product information
References link to published literature, regulator pages or literature indexes. Where a link points to a search, it collects the peer-reviewed work on that molecule rather than a single study.
Related
Related peptides
Other entries in Cognitive & neuro.
Cognitive & neuro
ACTH 4-10 (Org 2766)
The nerve-acting fragment of ACTH, developed as a drug candidate for nerve damage and cognitive decline, and abandoned.
Cognitive & neuro
BDNF (brain-derived neurotrophic factor)
The brain's main growth factor for plasticity: essential, widely measured, and not something a supplement can deliver.
Cognitive & neuro
Cerebrolysin
A porcine brain peptide mixture licensed in parts of Eastern Europe and Asia for stroke and dementia, without EMA or FDA approval.